METHODS FOR TESTING OF THERAPEUTIC COMPOUNDS

The present invention is related to a method for determining the efficacy of a chemical compound for treatment of recurrent herpes virus infection, said method comprising: (a) inoculating herpes virus at a primary skin site of a non-human mammal to cause zosteriform spread of the virus through nerve...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	KRISTOFFERSON, ANN
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention is related to a method for determining the efficacy of a chemical compound for treatment of recurrent herpes virus infection, said method comprising: (a) inoculating herpes virus at a primary skin site of a non-human mammal to cause zosteriform spread of the virus through nerve cells to cause lesions at a secondary (distal) site of infection; (b) before the appearance of skin lesions at the secondary site caused by the virus, giving adoptive transfer of immunity (ATI) to the said non-human mammal, so as to provide immunity mimicking the immunological reactivity seen in a recurrent herpes virus infection in a previously infected immune host; (c) administering a chemical compound to be tested to the said non-human mammal; and (d) determining the ability of the said chemical compound to reduce the occurrence and/or severity of herpes virus-induced skin lesions at the secondary site of infection.